NCT02585440View on ClinicalTrials.gov

A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

September 30, 2016

Conditions
Infectious Disease
Interventions
DRUG

CMX157

Oral tablet

DRUG

placebo

Oral tablet

Trial Locations (1)

Unknown

Bangkok

Sponsors
All Listed Sponsors
lead

ContraVir Pharmaceuticals, Inc.

INDUSTRY